Pharma Focus Asia

Science 37 and Novartis Sign Strategic Alliance to Advance Decentralized Clinical Trials

Wednesday, March 07, 2018

Science 37, a trailblazing company focused on “site-less” clinical trials, announced today a strategic alliance with Novartis that will support the development of its new decentralized clinical trial (DCT) offerings. This three-year commitment will enable a more extensive portfolio of trials powered by the Network Oriented Research Assistant (NORA®), Science 37’s proprietary technology platform that enables patients to participate in clinical research regardless of their geographical location using mobile devices and telemedicine services.

Through this collaboration, Science 37 will share its knowledge of the emerging decentralized clinical trial (DCT) space and offer customized enterprise software solutions to power US-based trials in the areas of dermatology, neuroscience and oncology, scheduled to launch in 2018.

“We are excited to deepen our relationship with an industry leader in innovative drug development like Novartis. As one of our earliest investors and supporters, their senior leadership recognized the value proposition of our NORA® technology platform and ‘siteless’ clinical trial model,” said Noah Craft, MD, PhD, and co-founder and CEO of Science 37. “We are thrilled to launch this strategic alliance to accelerate our patient-centered scientific work together across these new therapeutic areas.”

Science 37’s proprietary digital “innovation layer” will be applied to further enhance Novartis’ leading clinical development programs, enabling collaborative online work streams for sharing its deep knowledge of DCTs, advising on study design, protocol, recruitment, and regulatory considerations over the course of this three-year commitment.

Science 37’s core offering is focused on leveraging technology and telemedicine to make clinical trials better for patients. By making clinical trial participation from home more accessible, the company is also directly working to address the lack of diversity represented in traditional trials. Currently less than 10 percent of minorities are represented in clinical trials and the percentage involved in cancer trials can be below two percent. Science 37’s telemedicine-based clinical research model, the Metasite™ or “site-less” trial, bridges the geographic gap that exists between many patients and leading clinical researchers.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024